VALIANT LABORATORIES LTD (VALIANTLAB) financials

VALIANT LABORATORIES LTD (VALIANTLAB) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1980, Valiant LaboratoriesLtd manufactures and deals in Pharmaceuticals and speciality chemicals[1]

Market Cap: ₹731Cr.
Current Price: ₹135
Stock P/E: 55.4
ROE: 1.75%
ROCE: 2.36%
Book Value: ₹58.9
Dividend Yield: 0.00%
52W High / Low: ₹135/49.5

In Jun 2026, VALIANT LABORATORIES LTD (VALIANTLAB) reported sales ₹73.42 Cr and net profit ₹9.48 Cr.

Annual TTM: sales ₹239 Cr, net profit ₹13 Cr.

Shareholding: Promoters 74.94% (Sep 2026), FIIs 0.07% (Sep 2026), DIIs 0.08% (Sep 2026), Public 24.91% (Sep 2026), No. of Shareholders 14,618% (Sep 2026).

VALIANTLAB quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	21.48	35.23	57.77	51.01	45.99	54.74	65.30	73.42
Expenses	28.21	34.61	53.94	48.65	45.93	54.50	60.79	60.92
Operating Profit	-6.73	0.62	3.83	2.36	0.06	0.24	4.51	12.50
OPM %	-31.33%	1.76%	6.63%	4.63%	0.13%	0.44%	6.91%	17.03%
Other Income	1.93	0.67	0.65	0.67	0.85	0.61	0.77	0.85
Interest	0.01	0.06	0.05	0.07	0.14	0.03	0.02	0.08
Depreciation	0.51	0.51	0.51	0.51	0.51	0.72	0.52	0.55
Profit before tax	-5.32	0.72	3.92	2.45	0.26	0.10	4.74	12.72
Tax %	12.41%	-122.22%	17.60%	25.71%	34.62%	80.00%	25.32%	25.55%
Net Profit	-5.98	1.60	3.24	1.82	0.17	0.03	3.53	9.48
EPS in Rs	-1.10	0.29	0.60	0.34	0.03	0.01	0.65	1.75
Raw PDF	—	—	—	—	—	—	—	—

VALIANTLAB profit and loss (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	182	292	334	182	133	217	239
Expenses	132	249	299	190	138	210	222
Operating Profit	50	42	35	-8	-5	7	17
OPM %	27%	15%	11%	-4.6%	-3.5%	3.3%	7%
Other Income	1	2	5	10	5	3	3
Interest	2	0	0	0	0	0	0
Depreciation	3	2	2	2	2	2	2
Profit before tax	47	42	38	-1	-1	8	18
Tax %	35%	34%	24%	-145%	49%	26%	—
Net Profit	31	28	29	0	-2	6	13
EPS in Rs	—	6.74	7.13	0.06	-0.40	1.02	2.44
Dividend Payout %	0%	0%	0%	0%	0%	0%	—

VALIANTLAB balance sheet (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	10	16	33	43	43	54
Reserves	78	55	68	193	191	265
Borrowings	1	61	60	60	60	1
Other Liabilities	17	49	52	28	23	65
Total Liabilities	106	182	213	325	317	386
Fixed Assets	20	22	30	32	30	30
CWIP	0	1	0	0	0	0
Investments	0	0	34	119	165	191
Other Assets	87	158	149	174	122	165
Total Assets	106	182	213	325	317	386

VALIANTLAB cash flows (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	9	2	23	49	-22	-14
Cash from Investing Activity	-17	-12	-21	-183	25	-8
Cash from Financing Activity	11	6	-2	136	-0	20
Net Cash Flow	4	-4	0	2	3	-2
Free Cash Flow	7	-5	16	45	-22	-15
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	51%	40%	91%	-569%	537%	-178%

VALIANTLAB shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	74.94%	74.94%	74.94%	74.94%	74.94%	74.94%	74.94%	74.94%
FIIs	0.00%	0.64%	0.63%	0.02%	0.01%	0.20%	0.00%	0.07%
DIIs	0.00%	0.00%	0.46%	0.00%	0.00%	0.00%	0.00%	0.08%
Public	25.06%	24.42%	23.97%	25.05%	25.05%	24.87%	25.06%	24.91%
No. of Shareholders	15,692	15,036	14,432	15,075	14,910	14,657	14,341	14,618

VALIANTLAB key ratios
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	85	139	97	92	197	140
Inventory Days	18	25	17	22	12	45
Days Payable	37	72	62	54	61	118
Cash Conversion Cycle	66	91	52	60	149	67
Working Capital Days	102	109	106	97	194	158
ROCE %	—	38%	26%	-2%	-1%	2%

VALIANTLABUpdated 17 Oct 2026, 17:02

Valiant Laboratories Ltd

VALIANTLABUpdated 17 Oct 2026, 17:02

Market Cap

₹731Cr.

Current Price

₹135

High / Low

₹135/49.5

Stock P/E

55.4

ROE1.75%

ROCE2.36%

Book Value₹58.9

Face Value₹10.0

Dividend Yield0.00%

About

Incorporated in 1980, Valiant LaboratoriesLtd manufactures and deals in Pharmaceuticals and speciality chemicals[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	51.41	0.02	47.59	2.44	0.46	5.78	26.12	4.27	1.05
Sep 2023	59.55	0.02	60.94	2.96	0.49	1.06	25.47	0.79	0.19
Dec 2023	40.52	0.02	46.83	1.78	0.49	-5.04	-30.75	-3.5	-0.64
Mar 2024	30.58	0.02	35.11	2.5	0.5	-2.55	-52.16	-1.22	-0.22
Jun 2024	18.88	0.05	21.27	2.17	0.5	-0.77	31.17	-1.01	-0.19
Sep 2024	21.48	0.01	28.21	1.93	0.51	-5.32	12.41	-5.98	-1.1
Dec 2024	35.23	0.06	34.61	0.67	0.51	0.72	-122.22	1.6	0.29
Mar 2025	57.77	0.05	53.94	0.65	0.51	3.92	17.6	3.24	0.6
Jun 2025	51.01	0.07	48.65	0.67	0.51	2.45	25.71	1.82	0.34
Sep 2025	45.99	0.14	45.93	0.85	0.51	0.26	34.62	0.17	0.03
Dec 2025	54.74	0.03	54.5	0.61	0.72	0.1	80	0.03	0.01
Mar 2026	65.3	0.02	60.79	0.77	0.52	4.74	25.32	3.53	0.65
Jun 2026	73.42	0.08	60.92	0.85	0.55	12.72	25.55	9.48	1.75

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2021	182	2	132	1	3	47	35	31	—
Mar 2022	292	0	249	2	2	42	34	28	6.74
Mar 2023	334	0	299	5	2	38	24	29	7.13
Mar 2024	182	0	190	10	2	-1	-145	0	0.06
Mar 2025	133	0	138	5	2	-1	49	-2	-0.4
Mar 2026	217	0	210	3	2	8	26	6	1.02
TTM	239	0	222	3	2	18	—	13	2.44

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	74.94%
FIIs	0.07%
DIIs	0.08%
Public	24.91%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	74.94%	7.08%	0.43%	17.54%
Mar 2024	74.94%	3.48%	0%	21.58%
Jun 2024	74.94%	1.89%	0%	23.18%
Sep 2024	74.94%	0%	0%	25.06%
Dec 2024	74.94%	0%	0%	25.06%
Mar 2025	74.94%	0.64%	0%	24.42%
Jun 2025	74.94%	0.63%	0.46%	23.97%
Sep 2025	74.94%	0.02%	0%	25.05%
Dec 2025	74.94%	0.01%	0%	25.05%
Mar 2026	74.94%	0.2%	0%	24.87%
Jun 2026	74.94%	0%	0%	25.06%
Sep 2026	74.94%	0.07%	0.08%	24.91%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2021	10	78	1	17	106	20	0	0	87	106
Mar 2022	16	55	61	49	182	22	1	0	158	182
Mar 2023	33	68	60	52	213	30	0	34	149	213
Mar 2024	43	193	60	28	325	32	0	119	174	325
Mar 2025	43	191	60	23	317	30	0	165	122	317
Mar 2026	54	265	1	65	386	30	0	191	165	386

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2021	9	-17	11	4
Mar 2022	2	-12	6	-4
Mar 2023	23	-21	-2	0
Mar 2024	49	-183	136	2
Mar 2025	-22	25	0	3
Mar 2026	-14	-8	20	-2

Key ratios

Historical financial ratios

Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	85	139	97	92	197	140
Inventory Days	18	25	17	22	12	45
Days Payable	37	72	62	54	61	118
Cash Conversion Cycle	66	91	52	60	149	67
Working Capital Days	102	109	106	97	194	158
ROCE %	—	38%	26%	-2%	-1%	2%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of VALIANT LABORATORIES LTD (VALIANTLAB)?

The reported market capitalisation for VALIANT LABORATORIES LTD (VALIANTLAB) is ₹731Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of VALIANTLAB?

The current price shown for VALIANT LABORATORIES LTD (VALIANTLAB) on Fincrux is ₹135 with a 52-week high/low of ₹135/49.5.

What is the P/E ratio of VALIANT LABORATORIES LTD (VALIANTLAB)?

The stock P/E for VALIANT LABORATORIES LTD (VALIANTLAB) is 55.4 on Fincrux, with ROE at 1.75% and ROCE at 2.36%.

What were VALIANTLAB latest quarterly results?

For Jun 2026, VALIANT LABORATORIES LTD (VALIANTLAB) reported sales ₹73.42 Cr and net profit ₹9.48 Cr (figures in ₹ crore unless noted).

What are VALIANTLAB annual sales and net profit?

For TTM, VALIANT LABORATORIES LTD (VALIANTLAB) shows sales of ₹239 Cr and net profit of ₹13 Cr on the Fincrux profit & loss statement.

Who owns VALIANT LABORATORIES LTD (VALIANTLAB)?

Latest shareholding for VALIANT LABORATORIES LTD (VALIANTLAB) on Fincrux: Promoters 74.94% (Sep 2026), FIIs 0.07% (Sep 2026), DIIs 0.08% (Sep 2026), Public 24.91% (Sep 2026), No. of Shareholders 14,618% (Sep 2026).

Where can I find VALIANT LABORATORIES LTD (VALIANTLAB) financials?

VALIANT LABORATORIES LTD (VALIANTLAB) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show VALIANTLAB balance sheet and cash flow?

Yes. The VALIANT LABORATORIES LTD (VALIANTLAB) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 17 October 2026 at 17:02